Trial
NCT04916236
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
The Netherlands Cancer Institute
Collaborators
Lustgarten Foundation
Condition
Pancreatic Cancer
Intervention
RMC-4630
Why stopped
Due to a lack of safety and efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-24